Using a Dynamic Model to Estimate the Cost-Effectiveness of HPV Vaccination in Iran

被引:0
|
作者
Hagens, Arnold [1 ,2 ]
Sloof, Albertus Constantijn [3 ]
Janghorban, Roksana [4 ]
机构
[1] Univ Groningen RUG, Univ Med Ctr Groningen, Dept Hlth Sci, NL-9713 AV Groningen, Netherlands
[2] Triangulate Hlth Ltd, Doncaster DN11 9QU, England
[3] Asc Acad BV, NL-9725 AK Groningen, Netherlands
[4] Shiraz Univ Med Sci, Maternal Fetal Med Res Ctr, Sch Nursing & Midwifery, Dept Midwifery, Shiraz 7193613119, Iran
关键词
human papillomavirus; vaccine; cost-effectiveness; low- and middle-income countries; cervical cancer; quality-adjusted life years; HUMAN-PAPILLOMAVIRUS VACCINATION; CANCER; ADULTS;
D O I
10.3390/vaccines12040438
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study aimed to determine the cost-effectiveness of vaccination against HPV. An age-sex structured dynamic disease transmission model was created to estimate the spread of HPV and the HPV-related incidence of cervical cancer (CC) in Iran. Sixteen age groups of men and women were incorporated to reflect the differences in sexual preferences, vaccination uptake, and disease-related outcomes. Three scenarios were evaluated by using an Incremental Cost-Effectiveness Ratio (ICER) with gained quality-adjusted life years (QALYs). ICER values below one gross domestic product (GDP) per capita are evaluated as highly cost-effective. Vaccination reduces the number of infections and CC-related mortality. Over time, the vaccinated group ages and older age groups experience protection. An initial investment is required and savings in treatment spending reduce the impact over time. Vaccinating girls only was found to be cost-effective, with an ICER close to once the GDP per capita. Vaccinating both sexes was shown to be less cost-effective compared to girls only, and vaccinating boys only was not found to be cost-effective, with an ICER between once and three times, and greater than three times the GDP per capita, respectively. The estimates are conservative since societal cost-saving and the impact of other HPV-related illnesses were not considered and would likely reduce the ICERs.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF QUADRIVALENT HPV VACCINATION IN GERMANY USING A DYNAMIC TRANSMISSION MODEL
    Schobert, D.
    Remy, V
    Schoeffski, O.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A273 - A273
  • [2] Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model
    Schobert, Deniz
    Remy, Vanessa
    Schoeffski, Oliver
    [J]. HEALTH ECONOMICS REVIEW, 2012, 2
  • [3] Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model
    Deniz Schobert
    Vanessa Remy
    Oliver Schoeffski
    [J]. Health Economics Review, 2 (1)
  • [4] ESTIMATING THE POTENTIAL COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATION IN GERMANY USING A DYNAMIC TRANSMISSION MODEL
    Damm, O.
    Horn, J.
    Kretzschmar, M.
    Delere, Y.
    Kaufmann, A. M.
    Wichmann, O.
    Kraemer, A.
    Greiner, W.
    Mikolajczyk, R.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A452 - A452
  • [5] Cost-effectiveness of HPV vaccination in Belize
    Walwyn, Leslie
    Janusz, Cara Bess
    Clark, Andrew David
    Prieto, Elise
    Waight, Eufemia
    Largaespada, Natalia
    [J]. VACCINE, 2015, 33 : A174 - A181
  • [6] COST-EFFECTIVENESS ANALYSIS OF HPV VACCINATION IN SLOVENIA
    Obradovic, M.
    Mrhar, A.
    Kos, M.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A272 - A272
  • [7] COST-EFFECTIVENESS OF QUADRIVALENT HPV VACCINATION IN FINLAND
    Vaananen, J. J. P.
    Herse, F.
    Korkeamaki, J.
    Parvinen, P. M. T.
    Remy, O.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A431 - A431
  • [8] Cost-effectiveness of nonavalent HPV vaccination in the Netherlands
    Palmer, Cody
    Dolk, Christiaan
    Sabale, Ugne
    Wang, Wei
    Saxena, Kunal
    [J]. EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 312 - 323
  • [9] Cost-effectiveness of HPV 16, 18 vaccination in Brazil
    Goldie, Sue J.
    Kim, Jane J.
    Kobus, Katie
    Goldhaber-Fiebert, Jeremy D.
    Salomon, Joshua
    O'Shea, Meredith K. H.
    Xavier Bosch, F.
    de Sanjose, Silvia
    Franco, Eduardo L.
    [J]. VACCINE, 2007, 25 (33) : 6257 - 6270
  • [10] The cost-effectiveness of male HPV vaccination in the United States
    Chesson, Harrell W.
    Ekwueme, Donatus U.
    Saraiya, Mona
    Dunne, Eileen F.
    Markowitz, Lauri E.
    [J]. VACCINE, 2011, 29 (46) : 8443 - 8450